Sebelius Kathleen

Director Sebelius buys 56,818 HUMA shares at $0.88 (+62.3% position increase) while stock trades -68.6% from 52-week high.

Director Kathleen Sebelius purchased 56,818 shares at $0.88 on 2026-05-19, increasing her holdings by 62.3% to 148,025 shares. The purchase occurred when the stock was trading at $0.92, currently 68.6% below its 52-week high of $2.93, though up 33.8% over the prior 30 days. Humacyte remains unprofitable with net income of $-17.6M against quarterly revenue of $495.0K, and the company has a market cap of $204.3M. This buy represents a substantial position increase during a period of depressed valuation relative to recent highs.

Director Sebelius buys 50,000 HUMA shares at $1.32; cluster buy pattern with 2 other insiders in 14 days

Director Kathleen Sebelius purchased 50,000 shares of Humacyte, Inc. at $1.32 on April 8, 2025, increasing her holdings by 121.3% to 91,207 shares total—a substantial accumulation relative to her prior position. This transaction is part of a cluster pattern: 2 other insiders also bought within the same 14-day window, suggesting coordinated or contemporaneous conviction at this price level. The stock has since declined sharply, trading at $1.15 (current price) and down 87.8% from its 52-week high of $9.46, with a 75.4% decline over the past 90 days. Against this backdrop, Humacyte remains unprofitable (latest quarter revenue $241.0K, net income $-39.2M) with a market cap of $178.4M, creating a stark contrast between insider accumulation and deteriorating price action. The cluster buy pattern warrants monitoring to assess whether insiders possess information not yet reflected in public disclosures.